Compare Ascendis Pharma A/S (ASND) vs YieldMax COIN Option Income Strategy ETF (CONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs YieldMax COIN Option Income Strategy ETF — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while YieldMax COIN Option Income Strategy ETF trades at $19.24. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ASND | CONY | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $277.18 | $103.20 |
52-Week Low | $163.32 | $18.43 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CONY trades at $19.63 with a modest 0.31% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains a high distribution yield strategy, with recent weekly dividends ranging from $0.24 to $0.56. Financial ratios are unavailable in the current dataset, limiting fundamental assessment.
The outlook remains cautious due to the bearish technical setup and concerns about long-term sustainability of high distributions amid underlying asset volatility. While the yield strategy attracts income-focused investors, the 37% decline noted in recent analysis highlights significant price erosion that distributions have not offset.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →
